• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Bangalore, Jan. 10 Cellworks Research India Ltd, Bangalore, said its systems biology solution has shown good results in an ongoing drug discovery programme of Orchid Chemicals & Pharmaceuticals Ltd.

Orchid is the first Indian pharma company to adopt Cellworks’ systems biology technology to improve efficacy in its research for a new chemical entity for inflammation disorders, said the R&D wing of California-based Cellworks Group Inc.

The two began their collaboration in early 2006. The aim was to identify the mechanism of action of key drugs that are being used in industry to treat inflammation disorders.

According to Dr C. Bhaktavatsala Rao, Deputy Managing Director, Orchid Chemicals, “We were able to quickly ascertain which biological receptor target to focus on”, by adopting the Cellworks systems biology platform. It would help to develop better drugs with fewer side-effects, he said.

According to Dr Anandkumar, Chairman, board of Cellworks Research India Ltd, “The collaboration between Orchid Chemicals and Cellworks is ongoing in different drug discovery areas pertaining to inflammation.”

More Stories on : Research & Development | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
People’s car – a history

Copyright © 2008, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line